linezolid thrombocytopenia | Risk factors for linezolid-induced thromb

Keyword	CPC	PCC	Volume	Score	Length of keyword
linezolid thrombocytopenia	1.93	0.1	1494	72	26
linezolid	0.24	0.4	452	69	9
thrombocytopenia	0.24	0.4	9337	52	16

Keyword	CPC	PCC	Volume	Score
linezolid thrombocytopenia	0.71	0.1	9009	38
linezolid thrombocytopenia timing	1.59	0.7	2390	92
linezolid thrombocytopenia onset	1.52	0.4	7676	10
linezolid thrombocytopenia management	0.05	0.4	6478	57
linezolid thrombocytopenia duration	0.36	0.4	4198	6
linezolid thrombocytopenia treatment	0.95	0.1	7503	97
linezolid thrombocytopenia mechanism	1.23	0.9	6374	70
linezolid induced thrombocytopenia	1.32	0.6	3902	37
tedizolid vs linezolid thrombocytopenia	0.23	0.5	5996	38

Search Results related to linezolid thrombocytopenia on Search Engine

Risk factors for linezolid-induced thrombocytopenia in adult …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564787/

WEBNov 3, 2021 · Our study indicated that the relative risks of thrombocytopenia among patients receiving linezolid therapy for 7–14 days were 3.463 and 3.767 times higher than in patients receiving linezolid therapy for < 7 days for criterion-1 and -2 thrombocytopenia, respectively, and among patients receiving linezolid therapy for ≥ 14 days were 2.508 ...

DA: 46 PA: 1 MOZ Rank: 93

Real-Life Frequency of New-Onset Thrombocytopenia during Linezolid
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476580/

WEBApr 30, 2018 · The frequency of thrombocytopenia was 17.6% (18/102). For patients with thrombocytopenia, the mean lag time to the first thrombocytopenic platelet value (relative to initiation of linezolid) was 16 (SD 12) days. The mean time to the lowest thrombocytopenic platelet value was 21 (SD 15) days.

DA: 58 PA: 26 MOZ Rank: 87

Thrombocytopenia Associated with Linezolid Therapy | Clinical
oup.com

https://academic.oup.com/cid/article/34/5/695/319032

WEBMar 1, 2002 · Linezolid was associated with a significant (47%) decrease in platelet count even after only 10 days of therapy. These data suggest that even patients who are not considered to be at risk of developing thrombocytopenia should be monitored closely if linezolid therapy is continued for µ10 days.

DA: 68 PA: 68 MOZ Rank: 20

Drug-associated thrombocytopenia - American Society of …
ashpublications.org

https://ashpublications.org/hematology/article/2018/1/576/277620/Drug-associated-thrombocytopenia

WEBNov 30, 2018 · Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.

DA: 45 PA: 31 MOZ Rank: 87

Risk factors for linezolid-associated thrombocytopenia in adult
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226929/

WEBAug 14, 2014 · Thrombocytopenia (TP) is a common adverse effect of linezolid (LZD). However, risk factors for LZD-associated TP have been reported in Western patients with relatively heavy body weight. The aim of this study was to determine the risk factors for LZD-associated TP in Asian population.

DA: 23 PA: 20 MOZ Rank: 33

Linezolid-Induced Thrombocytopenia Is Caused by Suppression of ... - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/27803456/

WEBLinezolid (LZD) is an antimicrobial that is commonly used for treatment of vancomycin-resistant Enterococci and methicillin-resistant Staphylococcus aureus infections. However, the development of thrombocytopenia, one of the most frequent adverse side effects of this antimicrobial, can lead to discontinuation of LZD treatment.

DA: 54 PA: 77 MOZ Rank: 41

Reversible recurrent profound thrombocytopenia due to linezolid ... - LWW
lww.com

https://journals.lww.com/md-journal/Fulltext/2018/08240/Reversible_recurrent_profound_thrombocytopenia_due.91.aspx

WEBMay 13, 2018 · Thrombocytopenia caused by linezolid (LZD) is common, with a reported prevalence as high as 11.8%. Platelets typically reach normal levels 7 days after LZD withdrawal. However, recurrent profound thrombocytopenia due to LZD usage and a persistent profound drop in platelet count after LZD withdrawal have not been reported. …

DA: 55 PA: 9 MOZ Rank: 1

Safety of linezolid in patients with baseline thrombocytopenia
oup.com

https://academic.oup.com/jac/article/62/4/850/733359

WEBJul 2, 2008 · Thrombocytopenia (TCP) is a known risk factor (RF) associated with linezolid, most often manifesting after 2 weeks of therapy. 1, 2 The rate of TCP was 2.4% (range 0.3% to 10%) in clinical trials; 1 however, post-marketing surveillance revealed an incidence of TCP [defined variably as platelet (PLT) counts of ≤100 000 to ≤150 000/µL] …

DA: 78 PA: 87 MOZ Rank: 68

Risk factors for thrombocytopenia in patients receiving …
springer.com

https://link.springer.com/content/pdf/10.1007/s00228-023-03542-z.pdf

WEBRisk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis. NA 48.4. Yes 38.7. 13.9 IV/PO. NA 53.1. 13.4 IV. Yes 53.2. 9.6 IV/PO. 16.0 IV. Yes 48.8. Yes 60.5. PLTC < 100 × 10 9. /L . and ≥ 25% decrease in . PLTC from the baseline. PLTC < 50 × 109/L .

DA: 30 PA: 82 MOZ Rank: 58

Risk factors for thrombocytopenia in patients receiving linezolid
springer.com

https://link.springer.com/article/10.1007/s00228-023-03542-z

WEBAug 14, 2023 · 1 Altmetric. Explore all metrics. Abstract. Purpose. The incidence of linezolid-induced thrombocytopenia (LIT) has been reported to vary widely across studies. We performed a meta-analysis to identify the risk factors for thrombocytopenia among patients who received linezolid treatment. Methods.

DA: 63 PA: 31 MOZ Rank: 6